JP2022500364A5 - - Google Patents

Info

Publication number
JP2022500364A5
JP2022500364A5 JP2021511641A JP2021511641A JP2022500364A5 JP 2022500364 A5 JP2022500364 A5 JP 2022500364A5 JP 2021511641 A JP2021511641 A JP 2021511641A JP 2021511641 A JP2021511641 A JP 2021511641A JP 2022500364 A5 JP2022500364 A5 JP 2022500364A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
μmol
use according
per
total amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021511641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500364A (ja
JP7634476B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051247 external-priority patent/WO2020056399A1/en
Publication of JP2022500364A publication Critical patent/JP2022500364A/ja
Publication of JP2022500364A5 publication Critical patent/JP2022500364A5/ja
Application granted granted Critical
Publication of JP7634476B2 publication Critical patent/JP7634476B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021511641A 2018-09-16 2019-09-16 関節への送達に適した医薬組成物及びその関節痛の治療における使用 Active JP7634476B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731941P 2018-09-16 2018-09-16
US62/731,941 2018-09-16
PCT/US2019/051247 WO2020056399A1 (en) 2018-09-16 2019-09-16 Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Publications (3)

Publication Number Publication Date
JP2022500364A JP2022500364A (ja) 2022-01-04
JP2022500364A5 true JP2022500364A5 (enExample) 2024-07-22
JP7634476B2 JP7634476B2 (ja) 2025-02-21

Family

ID=68084954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021511641A Active JP7634476B2 (ja) 2018-09-16 2019-09-16 関節への送達に適した医薬組成物及びその関節痛の治療における使用

Country Status (15)

Country Link
US (1) US12208104B2 (enExample)
EP (1) EP3849522A1 (enExample)
JP (1) JP7634476B2 (enExample)
KR (1) KR20210060559A (enExample)
CN (1) CN112702993A (enExample)
AU (1) AU2019339528B2 (enExample)
BR (1) BR112021004880A2 (enExample)
CA (1) CA3112234A1 (enExample)
CL (1) CL2021000627A1 (enExample)
IL (1) IL281513A (enExample)
MX (1) MX2021003030A (enExample)
SG (1) SG11202102400PA (enExample)
TW (1) TWI843751B (enExample)
WO (1) WO2020056399A1 (enExample)
ZA (1) ZA202101688B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230048066A (ko) * 2020-08-05 2023-04-10 티엘씨 바이오파머슈티컬즈 인코포레이티드 통증 조절용 관절내 코르티코스테로이드의 약학 조성물
WO2024230405A1 (zh) * 2023-05-05 2024-11-14 中南大学湘雅医院 氢氧化镁在制备治疗关节疼痛的药物中的应用
TW202519194A (zh) * 2023-11-03 2025-05-16 台灣微脂體股份有限公司 用於疼痛控制之關節內皮質類固醇的微脂體組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
EP1371362A1 (en) * 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
RU2660585C2 (ru) 2012-02-10 2018-07-06 Тайвэн Липосом Компани, Лтд. Фармацевтическая композиция для уменьшения осложнений применения стероидных препаратов при лечении офтальмологических заболеваний
SI2854769T1 (sl) 2012-07-05 2023-09-29 Taiwan Liposome Company, Ltd. Postopki za zdravljenje artritisa

Similar Documents

Publication Publication Date Title
Tamm et al. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice
AU2013267359C1 (en) Formulations and methods for vaginal delivery of antiprogestins
JP2006527193A5 (enExample)
JP2022500364A5 (enExample)
US20200253871A1 (en) Liposomal corticosteroids for treatment of inflammatory disorders in humans
JP2022523548A5 (enExample)
US20170281648A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
DE03754425T1 (de) Anwendungen die in Bezug stehen mit durch Wasser stabilisierte medizinische Aerosolformulierungen
Goldsmith et al. Budesonide/formoterol: a review of its use in asthma
JP2023546361A5 (enExample)
MX2007001567A (es) Medicamentos para tratar enfermedad respiratoria cronica.
Boulet Once-daily inhaled corticosteroids for the treatment of asthma
JP6502876B2 (ja) 筋ジストロフィーの治療に用いられるジエチル−[6−(4−ヒドロキシカルバモイル−フェニル−カルバモイルオキシ−メチル)−ナフタレン−2−イル−メチル]−アンモニウムクロリド
RU2021109952A (ru) Фармацевтические композиции, подходящие для суставной доставки, и их применение при лечении суставной боли
Vastagh et al. Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC
CN1306429A (zh) 糖皮质类固醇在制备治疗轻度/早期c opd(慢性阻塞性肺病)的药物中的应用
Kuhn Immunoglobulin E blockade in the treatment of asthma
Colice New developments in inhaled corticosteroids
Masekela et al. Asthma treatment in children: A pragmatic approach
JP2023537474A5 (enExample)
Zöllner Is adrenal suppression in asthmatic children reversible? A case series
RU2021102859A (ru) Способы уменьшения осложнений от внутрисуставного стероида
JP5220741B2 (ja) アンドラスト/グルココルチコイドの併用
JP2007533706A5 (enExample)
Pakes et al. Topical clobetasol propionate